Detecting hepatocellular carcinoma with the Delta-HLD blood test

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

HIDE is a proof-of-concept case-control observational study that tests a set of tumor-specific DNA methylation markers using Epiliquid's Delta-HLD platform. The platform combines enzymatic pre-treatment and multiplexed PCR with a bioinformatics pipeline to identify and rank methylation biomarkers in cfDNA. The study will enroll patients with histologically confirmed HCC (cases) and patients with liver cirrhosis but no evidence of cancer (controls) and will analyze paired plasma and liver tissue samples. Outcomes include diagnostic sensitivity, specificity, and concordance between plasma and tissue methylation signals.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically confirmed HCC (cases) or clinically confirmed liver cirrhosis without HCC (controls)
* Willing and able to provide informed consent
* Available paired plasma and liver tissue sample

Exclusion Criteria:

* Other active cancers
* Prior liver transplantation
* Known hereditary cancer syndromes
* Recent chemotherapy or antiviral treatment (\<3 months)

Where it's running

• Epiliquid
  Mendoza, Argentina Recruiting

Study contacts

• Study coordinator: Dr. Victoria Bocanegra, MD, PhD.
• Email: victoria.bocanegra@epiliquid.com
• Phone: +5492616603254

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Anatomic vs nonanatomic liver resection after conversion therapy for liver cancer

  This study tests whether removing more precisely targeted liver tissue (anatomic resection) works better than removing tissue more broadly (nonanatomic) for patients whose unresectable liver cancer became eligible for surgery after PD-1/PD-L1–based therapy.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT07927452

• Impact of Anesthesia on Inflammation and NETosis During HCC Ablation

  This study tests whether a propofol–fentanyl anesthesia plan with lidocaine during radiofrequency ablation for hepatocellular carcinoma affects inflammation and NETosis in patients with small tumors.

  Recruiting Iuliu Hatieganu University of Medicine and Pharmacy · Cluj-Napoca, Cluj · NCT07657897

• Pre-emptive topical indomethacin to prevent sorafenib-related hand-foot syndrome in advanced liver cancer

  This trial will test whether applying 1% indomethacin gel to both hands twice daily can reduce hand-foot syndrome in adults with advanced hepatocellular carcinoma starting sorafenib.

  Recruiting Phase 2 National Taiwan University Hospital · Taipei · NCT07560566

• Becotatug vedotin (MRG003) for previously treated advanced liver cancer with EGFR testing

  This study will test whether Becotatug vedotin (MRG003) helps people with advanced hepatocellular carcinoma whose cancer progressed after PD‑1/L1 therapy.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07536789

• TACE or Ablation With Sintilimab and Ipilimumab Before Surgery for Liver Cancer

  This study tests whether combining local tumor treatments with immunotherapy before surgery helps people with resectable hepatocellular carcinoma at higher risk of recurrence.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07487662

• Personalized adaptive second-line treatments for advanced liver cancer

  This trial tries different personalized second-line treatments to find which work best for people with advanced hepatocellular carcinoma after first-line immunotherapy-based regimens stop working.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07328009

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.